A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14139-14152

  Lazar, Vladimir ^a,z   Rubin, Eitan ^b   Depil, Stephane ^c   Pawitan, Yudi ^d   Martini, Jean François ^e   Gomez Navarro, Jesus ^f   Yver, Antoine ^g,ag,ah   Kan, Zhengyin ^e   Dry, Jonathan R ^g,ag,ah   Kehren, Jeanne ^h   Validire, Pierre ⁱ   Rodon, Jordi ^j   Vielh, Philippe ^a   Ducreux, Michel ^a,k   Galbraith, Susan ^g,ag,ah   Lehnert, Manfred ^f   Onn, Amir ^l   Berger, Raanan ^l   Pierotti, Marco A ^m   Porgador, Angel ^b   Pramesh, C S ⁿ   Ye, Ding wei ^o   Carvalho, Andre L ^p   Batist, Gerald ^q   Chevalier, Thierry Le ^a   Morice, Philippe ^a   Besse, Benjamin ^a   Vassal, Gilles ^a   Mortlock, Andrew ^g,ag,ah   Hansson, Johan ^d   Berindan Neagoe, Ioana ^r,s   Dann, Robert ^t   Haspel, Joel ^u   Irimie, Alexandru ^r,s   Laderman, Steve ^v   Nechushtan, Hovav ^w   Al Omari, Amal S ^x   Haywood, Trent ^y   Bresson, Catherine ^z   Soo, Khee Chee ^aa   Osman, Iman ^ab   Mata, Hilario ^ac   Lee, Jack J ^ac   Jhaveri, Komal ^ab   Meurice, Guillaume ^a   Palmer, Gary ^ad   Lacroix, Ludovic ^a   Koscielny, Serge ^a   Eterovic, Karina Agda ^ac   Blay, Jean Yves ^c   Buller, Richard ^e   Eggermont, Alexander ^a,k   Schilsky, Richard L ^ae   Mendelsohn, John ^ac   Soria, Jean Charles ^a,k   Rothenberg, Mace ^e   Scoazec, Jean Yves ^a,k   Hong, Waun Ki ^ac   Kurzrock, Razelle ^af   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c CENTRE LÉON BÉRARD   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

^e PFIZER INC   (United States)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^g ASTRAZENECA   (United Kingdom)

^h SANOFI   (France)

ⁱ INSTITUT MUTUALISTE MONTSOURIS   (France)

^j VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^k UNIVERSITÉ PARIS SACLAY   (France)

^l SHEBA MEDICAL CENTER   (Israel)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ TATA MEMORIAL HOSPITAL   (India)

^o FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^p Barretos Cancer Hospital Pio XII Foundation   (Brazil)

^q MCGILL UNIVERSITY   (Canada)

^r IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^s THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^t General Electric Healthcare   (United States)

^u ORACLE CORPORATION   (United States)

^v AGILENT TECHNOLOGIES   (United States)

^w HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^x KING HUSSEIN CANCER CENTER   (Jordan)

^y Blue Cross and Blue Shield Association   (United States)

^z WIN Consortium   (France)

^aa DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^ab NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^ac UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ad FOUNDATION MEDICINE   (United States)

^ae AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^af UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^ag Oncology IMED   (United States)

^ah Macclesfield   (United Kingdom)

more..

Author keywords

Algorithm; NSCLC; Pathway; Targeted therapies; Tri therapy

Indexed keywords

MICRORNA; ANTINEOPLASTIC AGENT; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; NON SMALL CELL LUNG CANCER; SIMPLIFIED INTERVENTIONAL MAPPING SYSTEM; TRANSCRIPTOMICS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; TRANSCRIPTOME;

EID: 84931037125     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3741     Document Type: Article

References (23)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin. 64:9-29 (2014). Cancer of the Lung and Bronchus-SEER Stat Fact Sheets http://seer.cancer.gov/statfacts/html/lungb.html. 2014.
2. American Lung Association. Lung Cancer Fact Sheet. http://www.lung.org/lung-disease/lung-cancer/resources/facts-figures/lung-cancer-fact-sheet.html. 2015.
3. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008; 26:2442-9.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 28;363: 93-703.
5. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014; 20:2249-5.
6. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimoore B, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366:883-892.
7. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget. 2014; 5:2349-54.
8. Menzies AM1, Long GV. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res. 2014; 15;20:2035-43.
9. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LA, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alaverez C, Cavazos A, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res. 2012; 18:2316-25.
10. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012; 18:6373-83.
11. Munoz J1, Swanton C, Kurzrock R. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book. 2013; 127-34.
12. The Cancer Genome Atlas Research Networks: Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511:543-50.
13. Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J, Job B, Meurice G, Ripoche H, Calza S, Hasmats J, Lundeberg J, Lacroix L, et al. Integrated molecular portrait of non-small cell lung cancers. BMC Medical Genomics. 2013; 6:53.
14. The Tumor Analysis Best Practices Working Group. Expression profiling-best practices for data generation and interpretation in clinical trials. Nature Reviews Genetics. 2004; 5, 229-237.
15. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Biostatistics. 2004; 5:557-72.
16. Benjamini Y, Hochberg Y. J Royal Statist Soc. Series B (Methodological). 1995; 571995:289-300.
17. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology. 2004; 3: 3.
18. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013; 339:1546-1558.
19. Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, Elledge SJ. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013; 155:948-62.
20. Hanahan D, Weinberg R. A. Hallmarks of Cancer: The Next Generation. Cell. 2011; 144: 646-674.
21. Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev. 2014; 40: 883-891.
22. Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL. Principles and methods of integrative genomic analyses in cancer. Nat Rev Cancer. 2014; 14:299-313.
23. S. Koscielny. Why Most Gene Expression Signatures of Tumours Have Not Been Useful in the Clinic. Sci. Transl. Med. 2010; 2:14ps2.